Clearside Biomedical Files Q1 2025 10-Q
Ticker: CLSDQ · Form: 10-Q · Filed: May 15, 2025 · CIK: 1539029
| Field | Detail |
|---|---|
| Company | Clearside Biomedical, Inc. (CLSDQ) |
| Form Type | 10-Q |
| Filed Date | May 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, warrants, R&D
TL;DR
Clearside's Q1 2025 10-Q is in: warrants exercised, R&D continues. Check financials.
AI Summary
Clearside Biomedical, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates. Key events include the exercise of common stock warrants on February 6, 2024, and the company's ongoing research and development activities. Financial data such as Additional Paid-In Capital as of December 31, 2023, and March 31, 2024, are also reported.
Why It Matters
This filing provides investors with an update on Clearside Biomedical's financial health and operational progress for the first quarter of 2025, including details on stock warrants and R&D.
Risk Assessment
Risk Level: medium — The company is in the pharmaceutical sector, which is inherently risky due to R&D costs, regulatory hurdles, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Quarterly financial reporting)
- 2023-12-31 — Additional Paid-In Capital Date (Prior year-end financial reporting)
- 2024-03-31 — Additional Paid-In Capital Date (Prior quarter-end financial reporting)
Key Players & Entities
- Clearside Biomedical, Inc. (company) — Filer
- 20250331 (date) — Reporting Period End Date
- 0000950170-25-072568 (accession_number) — Filing Accession Number
- Arctic Visions Limited (company) — Mentioned in relation to a date
- 2020-03-10 (date) — Date associated with Arctic Visions Limited
- 2024-02-06 (date) — Date of common stock warrant exercise
FAQ
What was the primary purpose of the filing?
The filing is a 10-Q, which provides a quarterly report on the company's financial performance and condition for the period ending March 31, 2025.
When did Clearside Biomedical exercise common stock warrants?
Common stock warrants were exercised on February 6, 2024.
What is Clearside Biomedical's Standard Industrial Classification?
Clearside Biomedical's SIC code is 2834, Pharmaceutical Preparations.
What is the company's fiscal year end?
Clearside Biomedical's fiscal year ends on December 31.
What specific stock incentive plans are mentioned?
The filing mentions the Two Thousands And Eleven Stock Incentive Plan and the Two Thousands And Sixteen Equity Incentive Plan.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Clearside Biomedical, Inc. (CLSDQ).